Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 3/20 | 0.33 |
| ▸ | MET | P08581 | 2/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26538145 | 0.74 | NPC1 (0.45) | ALDH1A1MAPT | |
| SCHEMBL15686694 | 0.74 | SCN5A (0.40) | ALDH1A1MAPTALOX15TDP1MET | |
| SCHEMBL12489666 | 0.71 | UGT2B7 (0.39) | MEN1KMT2AMETSCN5A | |
| SCHEMBL2179468 | 0.71 | SCN5A (0.38) | METSCN5A | |
| SCHEMBL30621189 | 0.71 | SLC6A2 (0.40) | SLC6A4SLC6A2SLC6A3MAPTPKM | |
| SCHEMBL4812150 | 0.69 | SLC6A2 (0.57) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL25475739 | 0.69 | SCN5A (0.36) | METSCN5A | |
| SCHEMBL7986824 | 0.68 | SLC6A2 (0.62) | SLC6A4SLC6A2SLC6A3 | |
| Bromide SCHEMBL11850319 | 0.68 | SLC6A2 (0.56) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL13476496 | 0.66 | SLC6A2 (1.00) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| CN-116802182-A | Pyrazolopyridine derivatives and uses thereof | 诺华股份有限公司 | 2023-09-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | SLC6A4 3594/4885SLC6A2 4268/4885SLC6A3 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.